Komori
Presentation materials for financial results8715Anicom Holdings,Inc.Financials (excluding banks)

Supplementary Financial Results Information for the Fiscal Year Ending March 2026

For the fiscal year ending March 2026, ordinary revenue increased, while ordinary profit and net income declined due to contract transfer costs and business investments. Ordinary revenue and ordinary profit exceeded the full-year plan, and for the fiscal year ending March 2027, the Company plans for ordinary revenue of ¥81.0 billion and ordinary profit of ¥5.0 billion.

Worth reading
87Important
Scored from 4 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
1398
¥ millions (year-on-year decrease in ordinary profit)
Wording
Definitive
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ending March 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥73,846 million +9.1%ordinary income
Ordinary income¥3,543 million-28.3%
Net income¥2,204 million-32.1%
Selling, general and administrative expenses¥20,706 million
Results for the three months of the current quarter
Number of new contracts acquired60,000 contracts
Number of medical cases215,480
Unit for number of medical casesEngagements
Full-year earnings forecast
Fiscal year ending March 2027
Ordinary revenue
¥81,000 million
Ordinary income
¥5,000 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Full-year plan achieved
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Earned premiums5,475
Incurred claims-4,165
Agency commissions-609
Catastrophe loss reserves-19
Investment income53
Investment Expenses236
Other Ordinary Income868
Other ordinary expenses-256
Selling, general and administrative expenses-2,982
New initiatives
  • Commercialization of the advanced medical services business centered on JARVIS Animal Medical Center Tokyo
  • Expansion of sales channels, including e-commerce, and concentration on core products and priority channels
  • Promotion of the “One Person, One Patent Strategy”
  • Strengthening product awareness and customer touchpoints through participation in Interpets 2026
Key KPIsA metric the company considers important as a management benchmark.
  • Number of contracts held1,392,772 Engagements
    Year on year against the same period last year+8.1%
  • New contracts266,231 Engagements
    Year on year against the same period last year+8.3%
  • Retention Rate88.5 %
    Year on year against the same period last yearUp 0.3 pt year on year
  • Claims paid4,872 thousand cases
    Year on year against the same period last year+6.8%
  • E/I loss ratio62.2 %
    Year on year against the same period last yearUp 1.6 pt year on year
  • Expense ratio based on earned premiums32.8 %
    Year on year against the same period last yearUp 0.5 pt year on year
  • Combined ratio95 %
    Year on year against the same period last yearUp 2.1 pt year on year
  • どうぶつ健活 applications258,626 Engagements
    Year on year against the same period last year+6.7%
  • Veterinary hospitals served7,044 Hospitals
    Year on year against the same period last year+1.1%
Segment results
Matching Services Business
Net Sales
¥2,270 million
Ordinary income
¥103 million
Health innovation business
Net Sales
¥573 million
Ordinary income
¥-308 million
Veterinary hospital operations
Net Sales
¥2,401 million
Ordinary income
¥-717 million
Medium-term management plan targets
Target fiscal yearFiscal year ending March 2028
Ordinary revenue¥80–85 billion
Ordinary income¥6.8–7.3 billion
ROEApproximately 12%
Loss ratioApproximately 61–62%
Expense ratioApproximately 30–31%
Combined ratioApproximately 92%
Financial targets
ROE
Medium-term targetApproximately 12%
Actual results for the fiscal year ending March 20267.7％
Number of employees
Changes during the period and hiring plan153 inventors
Payout ratio
Actual results for the fiscal year ending March 202630.2 %
Planned for the fiscal year ending March 202730.4 %
Acquisition of treasury shares
Actual results for the fiscal year ending March 2026¥1 billion
Planned for the fiscal year ending March 2027¥1 billion
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFiscal year ending March 2026
Net Sales¥73,846 million (ordinary income) (YoY +9.1%)
Ordinary income¥3,543 million (YoY -28.3%)
Net income¥2,204 million (YoY -32.1%)
Selling, general and administrative expenses¥20,706 million
Results for the three months of the current quarterNumber of new contracts acquired 60,000 contracts / Number of medical cases 215,480 / Unit for number of medical cases Engagements
Full-year earnings forecastFiscal year ending March 2027 Ordinary revenue ¥81,000 million / Ordinary income ¥5,000 million
Self-assessment against the planFull-year plan achieved
Segment resultsMatching Services Business Net Sales ¥2,270 million / Ordinary income ¥103 million / Year-on-year change in revenue Not disclosed / Year-on-year change in ordinary profit Not disclosed / Health innovation business Net Sales ¥573 million / Ordinary income ¥-308 million / Year-on-year change in revenue Not disclosed / Year-on-year change in ordinary profit Not disclosed / Veterinary hospital operations Net Sales ¥2,401 million / Ordinary income ¥-717 million / Year-on-year change in revenue Not disclosed / Year-on-year change in ordinary profit Not disclosed
Breakdown of Factors Affecting the ChangeEarned premiums 5,475 / Incurred claims -4,165 / Agency commissions -609 / Catastrophe loss reserves -19 / Investment income 53 / Investment Expenses 236 / Other Ordinary Income 868 / Other ordinary expenses -256 / Selling, general and administrative expenses -2,982
Key KPIsIndicator name Number of contracts held / Value 1,392,772 Engagements / Year on year against the same period last year 8.1 Engagements, Indicator name New contracts / Value 266,231 Engagements / Year on year against the same period last year 8.3 Engagements, Indicator name Retention Rate / Value 88.5 % / Year on year against the same period last year Up 0.3 pt year on year, Indicator name Claims paid / Value 4,872 thousand cases / Year on year against the same period last year 6.8 thousand cases, Indicator name E/I loss ratio / Value 62.2 % / Year on year against the same period last year Up 1.6 pt year on year, Indicator name Expense ratio based on earned premiums / Value 32.8 % / Year on year against the same period last year Up 0.5 pt year on year, Indicator name Combined ratio / Value 95 % / Year on year against the same period last year Up 2.1 pt year on year, Indicator name どうぶつ健活 applications / Value 258,626 Engagements / Year on year against the same period last year 6.7 Engagements, Indicator name Veterinary hospitals served / Value 7,044 Hospitals / Year on year against the same period last year 1.1 Hospitals
Number of employeesNumber of Employees Not disclosed / Changes during the period and hiring plan 153 inventors
Medium-term management plan targetsTarget fiscal year Fiscal year ending March 2028 / Ordinary revenue ¥80–85 billion / Ordinary income ¥6.8–7.3 billion / ROE Approximately 12% / Loss ratio Approximately 61–62% / Expense ratio Approximately 30–31% / Combined ratio Approximately 92%
Financial targetsROE Medium-term target Approximately 12% / Actual results for the fiscal year ending March 2026 7.7％
Payout ratioActual results for the fiscal year ending March 2026 30.2 % / Planned for the fiscal year ending March 2027 30.4 %
Acquisition of treasury sharesActual results for the fiscal year ending March 2026 ¥1 billion / Planned for the fiscal year ending March 2027 ¥1 billion / Number of Shares Not disclosed / Period Not disclosed
New initiativesCommercialization of the advanced medical services business centered on JARVIS Animal Medical Center Tokyo, Expansion of sales channels, including e-commerce, and concentration on core products and priority channels, Promotion of the “One Person, One Patent Strategy”, Strengthening product awareness and customer touchpoints through participation in Interpets 2026
Items this document does not state (13)
Operating profitGross Profit MarginOperating profit marginProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAnnual DividendCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Profit declined due to contract transfer costs from AXA Direct and investment in JARVIS Tokyo, while revenue increased as a result of acquiring new contracts, expanding peripheral businesses, and higher investment income.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Information for the Fiscal Year Ending March 2026 | Anicom Holdings,Inc. (8715) timely disclosure | Komori